8.61

0.70% 0.06

After Hours: 8.33 -0.28 -3.25%

Zevra Therapeutics Inc (ZVRA)

Overview News Price History Option Chain Discussions Forecast Stock Split

Zevra Therapeutics Inc stock is traded at $8.61, with a volume of 424.06K. It is up +0.70% in the last 24 hours and up +19.58% over the past month. Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With unique, data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.

Previous Close:

$8.55

Open:

$8.54

24h Volume:

424.06K

Relative Volume:

0.41

Market Cap:

$453.04M

Revenue:

$27.46M

Net Income/Loss:

$-46.05M

P/E Ratio:

-9.1596

EPS:

-0.94

Net Cash Flow:

$-33.83M

1W Performance:

+4.24%

1M Performance:

+19.58%

6M Performance:

+79.00%

1Y Performance:

+85.96%

1-Day Range:

$8.26

$8.65

1-Week Range:

$8.11

$8.67

52-Week Range:

$3.89

$8.95

Zevra Therapeutics Inc Stock (ZVRA) Company Profile

Name

Zevra Therapeutics Inc

Sector

Healthcare (1182)

Industry

Biotechnology (671)

Phone

(321) 939-3416

Address

1180 CELEBRATION BOULEVARD, SUITE 103, CELEBRATION

Employee

Twitter

Next Earnings Date

2024-11-12

Latest SEC Filings

ZVRA's Discussions on Twitter

Zevra Therapeutics Inc Stock (ZVRA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-17-23	Initiated	Maxim Group	Buy

Zevra Therapeutics Inc Stock (ZVRA) Latest News

02:50 AM

Zevra Therapeutics (ZVRA) to Release Earnings on Tuesday - MarketBeat

02:50 AM

Zevra Therapeutics (ZVRA) to Release Quarterly Earnings on Tuesday - MarketBeat

02:50 AM

04:03 AM

Vanguard Group Inc's Strategic Acquisition in Zevra Therapeutics Inc - GuruFocus.com

04:03 AM

Oct 31, 2024

Zevra Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Nov. 12, 2024 - The Manila Times

Oct 31, 2024

Oct 29, 2024

Earnings Preview: Zevra Therapeutics (ZVRA) Q3 Earnings Expected to Decline - Yahoo Finance

Oct 29, 2024

Oct 28, 2024

Sanctuary Advisors LLC Makes New $474,000 Investment in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - MarketBeat

Oct 17, 2024

Zevra therapeutics director Corey Watton buys $3,957 in stock - Investing.com India

Oct 17, 2024

Oct 16, 2024

Zevra therapeutics director Corey Watton buys $3,957 in stock By Investing.com - Investing.com Australia

Oct 16, 2024

Oct 14, 2024

Zevra Stock Surges Close to 70% in 3 Months: Here's Why - MSN

Oct 14, 2024

Oct 13, 2024

Brokerages Set Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Price Target at $20.83 - MarketBeat

Oct 13, 2024

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Short Interest Up 25.7% in September - MarketBeat

Oct 13, 2024

Oct 11, 2024

Zevra Therapeutics (NASDAQ:ZVRA) Stock Rating Reaffirmed by Cantor Fitzgerald - MarketBeat

Oct 11, 2024

Oct 10, 2024

A company insider recently bought 2,000 shares of Zevra Therapeutics Inc [ZVRA]. Should You Buy? - Knox Daily

Oct 10, 2024

Zevra Therapeutics to Participate in Rare Disease Panel at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC - The Manila Times

Oct 10, 2024

Zevra Therapeutics to Participate in Rare Disease Panel at the 2024 Maxim Healthcare Virtual Summit, Presented - EIN News

Oct 10, 2024

Oct 09, 2024